myAACR
Donate Today
myAACR
Donate Today

Progress Against Cancer

Home Patients, Caregivers, and Advocates Progress Against Cancer Research Page 109

Recent Progress

Screening Reduces Lung Cancer Mortality but is Underutilized

Screening Reduces Lung Cancer Mortality but is Underutilized

Screening for lung cancer using low-dose computed tomography (CT) was introduced in the United States in 2013. Recent data from the Centers for Disease Control and Prevention (CDC) showed that only one in eight people for whom lung cancer screening was recommended reported having been screened in the past year, even as long-term results from a large randomized clinical trial provided confirmation that screening reduces lung cancer death rates.

CANCER RESEARCH CATALYST
Learn More
Colorectal Cancer: Preventive Measures, a New Treatment Approach, and Mortality Disparities

Colorectal Cancer: Preventive Measures, a New Treatment Approach, and Mortality Disparities

The incidence of colorectal cancer – the fourth most common cancer diagnosed in the United States – has been steadily declining since the late 1990s. Despite this decrease, it is estimated that the lifetime risk of developing the disease is roughly one in 20 for those living in the United States. If the cancer is caught early when it is still localized, the five-year relative survival is almost 90 percent. However, if diagnosed after it has metastasized, the five-year relative survival is less than 15 percent.

CANCER RESEARCH CATALYST
Learn More
Marching Forward on Multiple Fronts: March is Multiple Myeloma Awareness Month

Marching Forward on Multiple Fronts: March is Multiple Myeloma Awareness Month

Multiple myeloma is a cancer of antibody-producing cells – called plasma cells – that accounts for approximately 1.8 percent of new cancer cases in the United States. Although it is a relatively uncommon cancer, those who are diagnosed face a five-year survival rate of only 52 percent. Patients who are diagnosed at an early stage generally have a better prognosis; however, almost all patients are diagnosed after the cancer has progressed to a more advanced stage.

CANCER RESEARCH CATALYST
Learn More
Search / Filter
Innovators in Discovery

AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.

Learn More
Also of Interest: